Fructose-induced severe hypertriglyceridemia and diabetes mellitus: a cautionary tale

Ana Dugic¹, Michael Kryk¹, Claudia Mellenthin², Christoph Braig¹, Lorenzo Catanese³, Sandy Petermann¹, Jürgen Kothmann³ and Steffen Mühldorfer¹

¹Department for Gastroenterology, Endocrinology and Metabolic Diseases, Bayreuth University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Bayreuth, Germany, ²Department of Surgery, HFR Fribourg, Fribourg, Switzerland, and ³Department for Nephrology, Angiology and Rheumatology, Bayreuth University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Bayreuth, Germany

Correspondence
should be addressed
to A Dugic

Email
dugica@gmail.com

Summary

Drinking fruit juice is an increasingly popular health trend, as it is widely perceived as a source of vitamins and nutrients. However, high fructose load in fruit beverages can have harmful metabolic effects. When consumed in high amounts, fructose is linked with hypertriglyceridemia, fatty liver and insulin resistance. We present an unusual case of a patient with severe asymptomatic hypertriglyceridemia (triglycerides of 9182 mg/dL) and newly diagnosed type 2 diabetes mellitus, who reported a daily intake of 15 L of fruit juice over several weeks before presentation. The patient was referred to our emergency department with blood glucose of 527 mg/dL and glycated hemoglobin (HbA1c) of 17.3%. Interestingly, features of diabetic ketoacidosis or hyperosmolar hyperglycemic state were absent. The patient was overweight with an otherwise unremarkable physical exam. Lipase levels, liver function tests and inflammatory markers were closely monitored and remained unremarkable. The initial therapeutic approach included i.v. volume resuscitation, insulin and heparin. Additionally, plasmapheresis was performed to prevent potentially fatal complications of hypertriglyceridemia. The patient was counseled on balanced nutrition and detrimental effects of fruit beverages. He was discharged home 6 days after admission. At a 2-week follow-up visit, his triglyceride level was 419 mg/dL, total cholesterol was 221 mg/dL and HbA1c was 12.7%. The present case highlights the role of fructose overconsumption as a contributory factor for severe hypertriglyceridemia in a patient with newly diagnosed diabetes. We discuss metabolic effects of uncontrolled fructose ingestion, as well as the interplay of primary and secondary factors, in the pathogenesis of hypertriglyceridemia accompanied by diabetes.

Learning points:

- Excessive dietary fructose intake can exacerbate hypertriglyceridemia in patients with underlying type 2 diabetes mellitus (T2DM) and absence of diabetic ketoacidosis or hyperosmolar hyperglycemic state.
- When consumed in large amounts, fructose is considered a highly lipogenic nutrient linked with postprandial hypertriglyceridemia and *de novo* hepatic lipogenesis (DNL).
- Severe lipemia (triglyceride plasma level > 9000 mg/dL) could be asymptomatic and not necessarily complicated by acute pancreatitis, although lipase levels should be closely monitored.
- Plasmapheresis is an effective adjunct treatment option for rapid lowering of high serum lipids, which is paramount to prevent acute complications of severe hypertriglyceridemia.

Background

Although hypertriglyceridemia is a common feature of T2DM, severe forms with triglyceride (TG) levels exceeding 2000 mg/dL are extremely rare in these patients, unless accompanied by diabetic ketoacidosis (DKA). Drinking fruit juice is a widely accepted health trend, as it is perceived as a source of vitamins and nutrients. However, fruit beverages are loaded with fructose, a simple sugar with potentially harmful effects. When consumed in high amounts, fructose can cause hypertriglyceridemia, insulin resistance and visceral fat deposition (1). Because commercial fruit juices are often advertised as having a health benefit, it becomes increasingly difficult for the general population to make healthy food choices. Therefore, it is of utmost significance to raise awareness about a negative impact of fruit beverages, especially in diabetic patients who are at an increased risk of serious metabolic disturbances.

The present case highlights the importance of excessive fructose ingestion as a contributory factor for severe hypertriglyceridemia in a patient with newly diagnosed T2DM.

Case presentation

A previously healthy 58-year-old Caucasian male was referred to the emergency department due to severe lipemia (TG 9182 mg/dL and cholesterol 1327 mg/dL) and elevated blood glucose of 572 mg/dL. The patient reported intentional weight loss of ~14 kg over the previous 4 weeks, with a diet comprising excessive amounts of commercial fruit juices of about 15 L per day and almost no solid foods. After having experienced blurred vision and tingling in his toes, he scheduled an appointment with his family physician who uncovered the above-mentioned laboratory abnormalities and referred him to our emergency department.

The patient was alert and oriented on admission, with unremarkable vital signs and BMI of 26.9 kg/m² (height 182 cm and weight 89 kg). The skin examination did not reveal any xanthomas or xanthelasmas. The patient's past medical history was completely unremarkable, and his family history was negative for diabetes or dyslipidemia. He was not taking any medications and had no history of tobacco, alcohol or illicit drug abuse.

Investigation

The initial venous blood gas analysis (VBG) revealed a pH of 7.35 and glucose above 450 mg/dL, exceeding the

upper linear analytical limit of the VBG machine at our emergency room. Urinalysis revealed marked glycosuria and the absence of ketonuria (Table 1). Taken together, clinical and laboratory findings confidently ruled out DKA and hyperosmolar hyperglycemic state (HHS).

Due to the extremely lipemic appearance of the centrifuged blood sample (Fig. 1), further serum chemistry analysis was possible only after the first plasmapheresis session was performed. The relevant laboratory values recorded over the hospital course are presented in Table 2. Lipase levels, inflammatory markers and clinical signs of pancreatitis were closely monitored and remained unremarkable throughout the hospital stay. No signs of arterial hypertension or renal function impairment were observed.

The initial HbA1c was 17.3% (reference range: 4.8–6.0%). Random C-peptide was taken at the glucose level of

Table 1 Initial laboratory values.

Laboratory test		Reference range
Venous blood gas		
pH	7.35	7.30–7.43
pCO ₂ (mmHg)	53.7	38–58
Glucose (mg/dL)	>450*	70–115
Base excess (mmol/L)	3.9	–1.9 to 4.5
Bicarbonate (mmol/L)	25	22–30
Anion gap (mmol/L)	8.7	3.0–11.0
Sodium (mmol/L)	130	135–143
Potassium (mmol/L)	4.3	3.6–4.5
Lactate (mg/dL)	24	<22
Blood chemistry		
BUN (mg/dL)	29	18–55
Creatinine (mg/dL)	0.96	0.81–1.44
eGFR (mL/min)	>60	>60
Bilirubin total (mg/dL)	0.6	<1.2
AST (U/L)	30	<50
ALT (U/L)	42	<50
GGT (U/L)	51	<55
ALP (U/L)	48	40–130
Amylase (U/L)	25	30–110
Lipase (U/L)	76	73–393
Urine test strip		
Specific gravity	1.020	
Glucose	+4	Negative
Protein	+1	Negative
Ketones	Negative	Negative
Leukocyte esterase	Negative	Negative

Venous blood gas and urine were analyzed on admission. The displayed blood chemistry values are those obtained after plasmapheresis, as blood sample was too lipemic to be analyzed on admission.

*Value exceeds the upper linear analytical limit of the VBG machine at our emergency room.

ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; GGT, gamma-glutamyl transferase.

Figure 1
Patient's blood sample after separation with lipemic layer on the top.

320 mg/dL after more than 24 h from the last i.v. insulin application and before plasmapheresis and was sent to the referral laboratory; the C-peptide value was 0.97 µg/L (reference range: 0.81–3.85 µg/L). Anti-glutamic acid decarboxylase (anti-GAD), islet cell (anti-ICA) and protein tyrosine phosphatase (anti-IA-2) autoantibodies were also tested before plasmapheresis and were negative, yielding a diagnosis of T2DM.

Lipoprotein electrophoresis was performed 2 days after the second plasmapheresis session (Table 3). The lipid constellation corresponded to type IV

dyslipidemia according to the Fredrickson classification of hyperlipoproteinemia.

Abdominal ultrasonography (USG) revealed signs of diffuse hepatic steatosis (USG stage 2). Gall bladder, pancreas, spleen, kidneys and abdominal aorta exhibited no imaging abnormalities. ECG and echocardiography revealed no signs of coronary artery disease.

Treatment

The patient was admitted to our intensive care unit and treated with i.v. volume and electrolyte resuscitation, insulin, supplemental glucose and prophylactic anticoagulation with heparin. After a steady glucose-level range of 250–300 mg/dL had been achieved, the patient was transitioned to a s.c. insulin regimen.

To avoid potentially fatal complications of hypercoagulability associated with severe hypertriglyceridemia, the decision was taken to initiate therapeutic plasmapheresis with a 4% serum albumin solution (polyethylene filter: Plasmaflo OP05®). Plasmapheresis was performed on the second and third days of admission, and this yielded an immediate reduction of triglyceride level (Fig. 2).

Outcome and follow-up

During the hospitalization, the patient was counseled on balanced nutrition with emphasis on deleterious effects of uncontrolled fruit juice drinking, such as weight gain, fatty liver and worsening of diabetes and hypertriglyceridemia. In the beginning, the patient was very skeptical toward his diagnosis and was reluctant to initiate antidiabetic therapy, both metformin and insulin. After several counseling sessions, he finally accepted to start insulin but only according to the sliding scale regimen. He was trained on insulin use and self-monitoring of blood glucose by our diabetes team. The patient was discharged home 6 days after admission on s.c. regular insulin according

Table 2 Relevant laboratory values recorded over the hospital course.

	Hospitalization day						2-week follow up	Reference range
	1	2	3	4	5	6		
Cholesterol (mg/dL)	1327	#	334	238	221	247	221	<200
Triglyceride (mg/dL)	9182	#	1603	770	633	698	419	<200
HDL-cholesterol (mg/dL)	*	#	23	17	19	22		>35
LDL-cholesterol (mg/dL)	*	*	*	*	*	*	133	<150
HbA1c %			17.3		15.5		12.7	4.8–6.0
HbA1c (IFCC) mmol/mol			166		146		115	28.9–42.1

*Value not computable; #lipemic.

HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Table 3 Lipoprotein electrophoresis performed in the referral laboratory 2 days after the last plasmapheresis sitting.

Lipid fraction		Reference range
Triglycerides (mg/dL)	851	<150
Cholesterol (mg/dL)	267	<200
Chylomicrones (mg/dL)	Negative	
VLDL (mg/dL)	169	<30
HDL (mg/dL)	17	>40
LDL (mg/dL)	79	<115
Lp(a) (mg/dL)	Negative	

HDL, high-density lipoproteins; LDL, low-density lipoproteins; Lp(a), lipoprotein (a); VLDL, very low-density lipoproteins.

to standard scale protocol. He was strongly advised to visit a diabetologist for further counseling and therapy optimization. On discharge, 100 mg aspirin daily and 40 mg atorvastatin daily were additionally prescribed. After having obtained lipoprotein electrophoresis results a few days later, we subsequently recommended switching atorvastatin to gemfibrozil 600 mg BID.

At a 2-week follow-up appointment with his family physician, his triglyceride level was 419 mg/dL, total cholesterol was 221 mg/dL and HbA1c was 12.7%.

Discussion

Diabetic dyslipidemia is a common feature of T2DM. It is characterized by a typical combination of elevated serum TG and a decrease in high-density lipoproteins (HDL) (2).

Severe forms (with TG levels exceeding 2000 mg/dL) are rarely encountered in patients with T2DM unless they are part of preexisting primary dyslipidemia. When caused by diabetes alone, severe hypertriglyceridemia is almost exclusively accompanied by DKA, which presents as a severe insulin deficit of type 1 diabetes. Less commonly, DKA can also be observed in T2DM, in which case it is

either linked to a long-standing disease characterized by insulin depletion or severe insulin resistance.

In this case, the absence of DKA and the presence of non-fasting random serum C-peptide at 0.97 µg/L (~0.32 nmol/L) at glucose levels above 300 mg/dL could exclude hyperinsulinemia or total insulin deficiency as a reason for uncontrolled hypertriglyceridemia (3). The amount of the patient's endogenous insulin has been sufficient to prevent excessive lipolysis and subsequent ketogenesis but not hyperglycemia, which is corroborated by the absence of DKA. Moreover, severe familial hyperlipidemia as an underlying cause of excessive TG levels was almost completely ruled out, as will be discussed in detail later. Even if preexisting hypertriglyceridemia and insulin resistance had been present to some extent, assumed based on the metabolic syndrome features the patient exhibited, this alone could not explain such extreme TG values. It became apparent that an additional mechanism must have been involved in such severe metabolic disturbances.

Surprisingly, severe hypertriglyceridemia in this patient appears to have been induced by excessive intake of fructose contained in commercial fruit juices. Mixed with glucose in approximately equal amounts, fructose is the main constituent of sugar-sweetened beverages. As part of his weight-loss plan (which the authors preferred to attribute to severe polydipsia), the patient ingested ~15 L of fruit juice per day. Given that an average commercial juice contains 8–11 g sugar per 100 mL, the presumed daily amount of ingested sugar exceeded 1.2 kg; the fructose-to-glucose ratio of commercial juices is ~60:40, yielding consumption of above 720 g fructose daily (4). Furthermore, this also led to excessive daily caloric intake, which exceeded daily dietary requirements and could have partly contributed to lipogenesis; however, due to the limited amount of the patient's insulin, this does not seem to have been the primary mechanism of lipid synthesis (5). The patient's low insulin levels may also explain his weight loss, despite his consumption of such a hypercaloric diet.

Figure 2

Triglyceride levels during hospital stay. The exact TG level could not be measured in our laboratory before plasmapheresis had been performed, but for graphical presentation, we included the initial value obtained by the referring physician (indicated by asterisk).

The anamnesis, clinical features of metabolic syndrome accompanied by insulin resistance, unremarkable family history and a newly diagnosed T2DM are all highly suggestive of the secondary cause of hypertriglyceridemia in this case. Furthermore, mild preexisting primary hyperlipidemia of Fredrickson type IV could also have been present in this patient (9). Although we could not determine the patient's previous lipid status

Downloaded from Bioscientifica.com at 04/26/2023 07:15:24AM
via free access

(he considered himself healthy and had not visited a doctor for years), he denied any family history of diabetes, cardiovascular disease or dyslipidemia. No xanthelasma, tuberous xanthomas or corneal arcus were present on physical examination. Echocardiography and abdominal ultrasonography revealed no signs of atherosclerosis despite his mature age. Finally, lipoprotein electrophoresis and 2-week follow-up values excluded LDL elevation. Consequently, the severe familial forms of hyperlipidemia (such as familial combined hyperlipidemia and familial hypertriglyceridemia) are highly unlikely causes for such extreme TG elevation in this case. Accordingly, we believe that hyperlipidemia was caused by insulin resistance through uncontrolled T2DM and further enhanced by excessive amounts of ingested fructose.

Severe hypertriglyceridemia requires rapid treatment, as it confers a significant risk of acute pancreatitis. It is a rare but well-defined cause of acute pancreatitis (alcohol and biliary etiology being most common), accounting for 2–4% of all cases (10). Interestingly, our patient did not have pancreatitis, although lipase levels were closely monitored throughout the hospital stay. Accordingly, severe hypertriglyceridemia is not necessarily complicated by acute pancreatitis. On the other side, a prothrombotic state has been reported in association with hypertriglyceridemia (11). To prevent potentially fatal complications of blood hypercoagulability, we employed plasmapheresis. The rapid decline in TG level immediately after plasmapheresis was in accordance with the assumption that hypertriglyceridemia was here partly driven by mechanisms that are not dependent on insulin.

In conclusion, severe hyperlipidemia might have been triggered by excessive fructose intake (>720 g per day) in a patient with uncontrolled, newly diagnosed T2DM, an absence of ketoacidosis and measurable serum C-peptide levels. The mechanism involves DNL. Acute pancreatitis does not necessarily complicate severe hypertriglyceridemia. Plasmapheresis is effective in rapid lowering of plasma lipids, which is paramount to prevent complications of hypercoagulability associated with extreme hypertriglyceridemia.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. The abstract of this manuscript was presented as a virtual poster at the annual European Pancreas Club meeting held online from June 9 to June 12, 2021.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Patient consent

Written informed consent for publication of their clinical details was obtained from the patient.

Author contribution statement

Study conception and design were done by A D, M K and S M. Acquisition of data was done by A D, M K, L C, J K. Analysis and interpretation of data were done by A D, M K, C M, C B, J K, S P and S M. Drafting of the manuscript was done by A D. Figure illustration was done by C M. Critical revision was done by M K, C M, C B, J K and S M. Guarantors of the article were A D and S M. All authors read and approved the final manuscript.

References

- Geidl-Flueck B, Hochuli M, Nemeth Á, Eberl A, Derron N, Kofeler HC, Tappy L, Berneis K, Spinas GA & Gerber PA. Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: a randomized controlled trial. *Journal of Hepatology* 2021 **75** 46–54. (<https://doi.org/10.1016/j.jhep.2021.02.027>)
- Haffner SM & American Diabetes Association. Management of dyslipidemia in adults with diabetes. *Diabetes Care* 2003 **26** (Supplement 1) S83–S86. (<https://doi.org/10.2337/diacare.26.2007.s83>)
- Jones AG & Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine* 2013 **30** 803–817. (<https://doi.org/10.1111/dme.12159>)
- Walker RW, Dumke KA & Goran MI. Fructose content in popular beverages made with and without high-fructose corn syrup. *Nutrition* 2014 **30** 928–935. (<https://doi.org/10.1016/j.nut.2014.04.003>)
- Tappy L & Rosset R. Health outcomes of a high fructose intake: the importance of physical activity. *Journal of Physiology* 2019 **597** 3561–3571. (<https://doi.org/10.1113/jp278246>)
- Kolderup A & Svihus B. Fructose metabolism and relation to atherosclerosis, Type 2 diabetes, and obesity. *Journal of Nutrition and Metabolism* 2015 **2015** 823081. (<https://doi.org/10.1155/2015/823081>)
- Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. *Journal of Clinical Investigation* 2009 **119** 1322–1334. (<https://doi.org/10.1172/JCI37385>)
- Stanhope KL, Medici V, Bremer AA, Lee V, Lam HD, Nunez MV, Chen GX, Keim NL & Havel PJ. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. *American Journal of Clinical Nutrition* 2015 **101** 1144–1154. (<https://doi.org/10.3945/ajcn.114.100461>)
- Fredrickson DS & Lees RS. A system for phenotyping hyperlipoproteinemia. *Circulation* 1965 **31** 321–327. (<https://doi.org/10.1161/01.cir.31.3.321>)
- Garg R & Rustagi T. Management of hypertriglyceridemia induced acute pancreatitis. *BioMed Research International* 2018 **2018** 4721357. (<https://doi.org/10.1155/2018/4721357>)
- Simpson HC, Mann JI, Meade TW, Chakrabarti R, Stirling Y & Woolf L. Hypertriglyceridaemia and hypercoagulability. *Lancet* 1983 **1** 786–790. ([https://doi.org/10.1016/s0140-6736\(83\)91849-4](https://doi.org/10.1016/s0140-6736(83)91849-4))

Received in final form 6 October 2021

Accepted 18 October 2021